LGM
VRNA

Logos Global Management’s Verona Pharma VRNA Stock Holding History

Logos Global Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300,000
Closed -$1.5M – 43
2022
Q1 		$1.5M Buy
300,000
+178,000
+146% +$1.04M 0.19% 37
2021
Q4 		$820K Buy
+122,000
New +$623K 0.08% 62

Other funds holding VRNA

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Logos Global Management's VRNA Position: Q2 2022 in Review

Logos Global Management sold out of Verona Pharma (VRNA) in Q2 2022, closing a stake of 300,000 shares — an estimated $1.5M sold.

Logos Global Management first reported a position in VRNA in Q4 2021 and held it in 2 quarters. The position peaked at $1.5M in Q1 2022. 40 funds tracked by Wall St. Rank hold VRNA as of Q2 2022.

  • Logos Global Management reported no remaining Verona Pharma position as of Q2 2022 after selling out during the quarter.
  • Logos Global Management sold 300,000 Verona Pharma shares in Q2 2022, an estimated $1.5M.
  • Logos Global Management first reported a position in Verona Pharma in Q4 2021 and held it in 2 quarters.
  • Logos Global Management's Verona Pharma position peaked at $1.5M in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2022.

Based on Logos Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.